Drugmaker Mayne Pharma Group, which has lost 59 per cent of its share market value over the past five years, is giving some thought to life away from the ASX boards.
Pubs baron Bruce Mathieson at Mayne’s 2016 AGM. Tracey Nearmy
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
